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Abstract: Objective: B cell-specific Moloney murine leukemia virus integration site 1 (BMI1), is a Plycomb group 
(PCG) protein, that is involved in the epithelial-mesenchymal transition (EMT) and induces stem cell properties, 
suggestive poor prognosis. In this study, we evaluated the prognostic value of BMI1 in cervical cancer. Methods: 
The study materials were comprised of cervical intraepithelial neoplasia (CIN, n=225), cervical cancer (n=150) and 
matched nonadjacent normal tissues (n=326). In order to identify BMI1 expression in the tissues, immunohisto-
chemistry (IHC) was performed. IHC scoring was performed using digital image analysis, and the associations of 
BMI1 with prognosis, radiation sensitivity and human papillomavirus level were examined. Results: BMI1 compared 
with normal cervix and CIN lesion was highly expressed in cervical cancer. High expression of BMI1 presented 
better disease-free survival and overall survival than low expression according to a Kaplan-Meier survival analysis 
(P=0.017 and 0.035, respectively), and produced a significantly low hazard ratio for death according to a multivari-
ate analysis (P=0.03). In CIN lesion, BMI1 was correlated with cancer stem cell (CSC) markers such as OCT4 and 
SOX2 (P=0.006 and 0.031, respectively), whereas in cervical cancer, no association was observed. Additionally, 
BMI1 expression was observed in radiation-sensitive cervical cancer, suggesting its positive prognostic indication. 
Conclusions: BMI1 expression is associated with favorable survival in cervical cancer, and as such, might aid the 
prognosis of cervical carcinoma.
Keywords: BMI, cervical cancer, prognosis
Introduction
Cervical cancer is the fourth most common 
malignancy in women worldwide; indeed, it re- 
mains a leading cause of women’s death [1]. 
Although cervical cancer can be detected ear- 
ly thanks to advanced screening systems and 
the fact that is symptomatic at early stages, 
advanced cases requiring multimodal treat-
ment including chemotherapy, radiation and 
other modalities continue to be diagnosed. Ch- 
emo-radiation therapy has produced favorable 
responses in patients with advanced cervical 
cancer. However, some cancer cells acquire re- 
sistance to chemo-radiation; difficult to fully 
eradicate, they are often the eventual cause of 
death. Cancer cells that are resistant to chemo-
therapy and radiotherapy have properties of 
cancer stem cells (CSCs) that are implicated in 
treatment failure [2, 3].
B cell-specific Moloney murine leukemia virus 
integration site 1 (BMI1) is one of the Polycomb 
group (PCG) proteins, that are involved in chro-
matic modification, suggesting cancer develop-
ment and maintenance of embryonic and adult 
stem cells [4]. BMI1 plays an important role as 
a transcriptional regulator through chromatin 
modification, and is involved in cell-cycle regu-
lation, hematopoiesis and senescence [5, 6]. 
Through chromatin and histone modification, 
BMI1 regulates cell cycle and self-renewal, spe-
cifically by suppressing the INK4a locus that 
inactivates tumor suppressors p16 and p14ARF 
[7, 8].
BMI1, unfortunately, is dysregulated in cancer 
cells; this is responsible for invasiveness and 
poor prognosis in various cancers [9]. BMI1 is 
involved in the epithelial-mesenchymal transi-
tion (EMT), which enhances metastasis and 
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induces cells with stem-like properties [9, 10]. 
BMI1 cooperates with Snail or Twist1, key regu-
lators of EMT, and promotes EMT through sup-
pression of PTEN/E-cadherin expression or 
repression of p16INK4a [9, 11, 12]. Cancer 
cells undergoing EMT also acquire cancer stem 
cell (CSC) properties, suggesting a crucial asso-
ciation [10]. BMI1 enhances tumorigenesis and 
stem cell properties and shows a correlation 
with stem cell markers in various cancer cells 
[13, 14]. In cisplatin-resistant oral squamous 
cell carcinoma, CSC properties are expanded, 
and BMI1 is highly expressed with stem cell 
markers including OCT4 and Nanog [15]. Also, 
BMI1 is a key mediator of SOX2 function, the 
connection between BMI1 and SOX2 being 
essential to self-renewal [16].
BMI1 expression is increased in various can-
cers including lung, colorectal, breast and oral, 
and its high expression is associated with poor 
prognosis [14, 17-19]. In light of such accumu-
lating evidence, it is expected that BMI1 plays a 
key role in tumorigenesis and cancer progno-
sis. However, its prognostic significance has 
been the subject of controversy, as improved 
survival outcomes have been reported for glio-
blastoma, breast and colorectal cancer patients 
showing high BMI1 expression [20-22]. Furth- 
ermore, prognosis of BMI1 in cervical cancer is 
not yet firmly established. In this study, we eval-
uated the protein expression of BMI1 by digital 
image analysis, on which basis we investigated 
the prognostic significance of BMI1 in cervical 
cancer. 
Materials and methods
Patient’ selection
A total of 375 patients with cervical cancer and 
cervical intraepithelial neoplasia (CIN) along 
with 323 matched normal patients from Ga- 
ngnam Severance Hospital, Yonsei University 
College of Medicine in Seoul, Korea and the 
Korea Gynecologic Cancer Bank were asses- 
sed as part of the Bio & Medical Technology 
Development Program of the Ministry of Ed- 
ucation, Science and Technology, Korea, be- 
tween 1996 and 2010. Medical records were 
reviewed for patient data including age, cancer 
stage, tumor differentiation, cell type, tumor 
size, lymphovascular invasion (LVI) and lymph 
node (LN) metastasis. The cervical cancers 
were histologically classified and graded ac- 
cording to the WHO classification and stag- 
ed according to the International Federation 
of Gynecology and Obstetrics (FIGO) stage. Ra- 
dical hysterectomy with pelvic and aortic LN 
dissection in patients with operable indica-
tions, and concurrent chemoradiation therapy, 
were added to the risk factors including LN 
metastasis, parametrial invasion and positive 
resection margin. The patients with inoperable 
conditions underwent radiation or chemoradia-
tion therapy. Those who recurred within 1 year 
of radiation or chemoradiation therapy were 
regarded as radiation sensitive. The current st- 
udy was approved by the Institutional Review 
Board of Gangnam Severance Hospital.
Table 1. Patients’ clinicopathologic character-
istics
Frequency %
Age 43.9*
Diagnostic category
    Normal 323 46.3
    CIN 225 32.2
    Cervical cancer 150 21.5
FIGO stage
    <IIA 108 72
    >IIB 42 28
Tumor differentiation
    Well to Moderate 108 73.5
    Poor 39 26.5
Cell type
    Squamous cell carcinoma 119 79.3
    Adenocarcinoma 15 10
    Others 16 10.7
Tumor size
    ≤4 cm 100 66.7
    >4 cm 50 33.3
Lymphovascular invasion†
    No 68 51.1
    Yes 65 48.9
Lymph node metastasis‡
   No 97 71.9
    Yes 38 28.1
CIN, cervical intraepithelial neoplasia; FIGO, International 
Federation of Gynecology and Obstetrics; *mean value; 
†calculated only 133 cases with available information 
on examined lymphovascular invasion, ‡calculated only 
135 cases with available information on examined lymph 
node.
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Tissue microarray construction and immuno-
histochemistry
Tissue microarrays (TMAs) were constructed 
from 375 formalin-fixed paraffin-embedded tis-
sue specimens. Meanwhile, 323 nonadjacent 
normal tissues were prepared as well. After the 
slides were reviewed by a pathologist, areas 
containing each category were indicated on 
H&E slides. 1 mm punches were then taken 
from the corresponding regions of the paraffin 
blocks and transplanted into a recipient paraf-
fin block using a tissue arrayer (Pathology De- 
vices, Westminster, MD).
For IHC staining, all TMA sections were cut to 5 
micron thickness followed by deparaffinizati- 
on through xylene and dehydration with graded 
ethanols. Antigen recovery was performed in 
heat-activated antigen retrieval pH6 (Dako, 
Carpinteria, CA) for BMI1, after which speci-
mens were incubated with 3% H2O2 for 10 min. 
Non-specific binding was blocked with protein 
block (Dako) for 20 min at room temperature. 
The sections were then incubated with anti-
BMI1 antibody (Sigma-Aldrich, St. Louis, MO) at 
1:100 for 1 hour. Subsequently, sections were 
incubated with DAKO Env+ secondary antibody 
for 30 min, visualized with 3,3-diaminobenza-
dine for 10 min for chromogenic development, 
and washed and counterstained with hematox-
ylin. Negative controls were concurrently per-
formed. The positive controls included normal 
cervix, esophageal and gastric epithelium for 
the BMI1 antibody.
Figure 1. Representative IHC expression of BMI1. BMI1 expression showing (A) no nuclear staining in normal cervix, 
(B) weak nuclear staining in CINII, (C) moderate nuclear staining in squamous cell carcinoma, and (D) strong nuclear 
staining in squamous cell carcinoma. Scale bar: 100 μm.
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Digital image analysis
Immunohistochemically stained whole sections 
were digitized at 20 × magnification and 0.50 
μm/pixel spatial resolution utilizing an Aperio 
Scanscope CS (Aperio, Vista, CA,). The images 
were reviewed utilizing an online software appli-
cation, Digital Image Hub (SlidePath, Dublin, 
Ireland), that enables users to annotate normal 
and tumor regions. Once the regions were an- 
notated, they were sent for automated image 
analysis utilizing Tissue IA (SlidePath’s Tissue 
IA system, version 3.0, Dublin, Ireland), which 
includes an algorithm developed for quantifica-
tion of BMI1. Briefly, BMI1 nuclei were stained, 
the intensity of which was categorized as 0 (no 
staining), 1+ (weak), 2+ (moderate) or 3+ (str- 
ong). BMI1 were interpreted according to wei- 
ghted histoscores (i.e., multiplied by the per-
centage of nuclear intensity) ranging from 0 to 
300: Histoscore = (0 × percentage not stained) 
+ (1 × percentage weakly stained) + (2 × per-
Inc., Chicago, IL). A value of P<0.05 was consid-
ered statistically significant.
Results
Clinicopathologic characteristics of patients
The patients’ clinicopathologic characteristics 
are summarized in Table 1. There were 225 CIN 
and 150 cervical cancers. Among the 150 
patients with cervical cancer, the number with 
stage I and IIA was 108, and the number with 
IIB and IV was 42. The patients’ mean age was 
43.9 years (range: 21-83 years). The tumor 
sizes ranged from 0.3 to 12 cm (mean: 3.0 cm). 
The cervical cancer tumors included 119 squa-
mous cell carcinoma (SCC), 15 adenocarcino-
ma, 8 adenosquamous and 8 other cell types 
(2 small cell carcinoma, 2 neuroendocrine, 4 
mixed cell types). In a survival analysis of 150 
patients, the mean follow-up time for survivors 
was 59.7 months (range: 1-187), during which 
19 patients (12.6%) died.
Table 2. Association of BMI1 expression with clinico-
pathologic characteristics
N Mean Histoscore (95% CI) P
Diagnostic category <0.001
    Normal 323 31.2 (27.3-35.1)
    CIN 225 35.6 (29.3-42.9)
    Cervical cancer 150 62.5 (50.6-74.5)
FIGO stage 0.256
    I 98 69.2 (53.5-85.1)
    II 46 47.5 (29.1-65.8)
    IV 6 69.1 (5.4-143.7) 0.770
Tumor differentiation
    Well + Moderate 88 64.2 (48.0-80.3)
    Poor 59 60.5 (41.6-79.3)
Cell Type 0.456
    Squamous cell carcinoma 119 60.2 (46.9-73.6)
    Others 31 71.4 (43.0-99.9)
Tumor size 0.391
    <4 cm 100 66.2 (50.8-81.7)
    ≥4 cm 50 55.2 (36.2-74.1)
Lymphovascular invasion 0.429
    Negative 68 59.0 (40.8-77.2)
    Positive 65 69.5 (50.3-88.7)
Lymph node metastasis 0.347
    Negative 97 67.3 (51.6-82.9)
    Positive 38 53.6 (30.5-76.7)
CI, confidence interval; CIN, cervical intraepithelial neoplasia; FIGO, 
International Federation of Gynecology and Obstetrics.
centage moderately stained) + (3 × percent-
age strongly stained) [23]. To investigate 
the association of BMI1 with CSC markers, 
OCT4 and SOX2 protein expressions, st- 
ained previously at this institution (data 
unpublished), were used.
Statistical analysis
The IHC scores were compared by one-way 
ANOVA and independent t-test. The his-
toscore cut-off for high expression of tumor 
markers was determined by receiver operat-
ing characteristic (ROC) curve analysis. The 
sensitivity and (1-specificity) for discriminat-
ing death or survival was determined for 
each IHC score and plotted, thus generating 
the ROC curve. The cut-off value was deter-
mined to be the point on the ROC curve 
where the sum of sensitivity and specificity 
was maximized. Kaplan-Meier survival anal-
ysis was performed to determine the asso-
ciations of BMI1 expression with disease-
free and overall survival, and the survival 
curves were compared between the groups 
using log-rank tests. Multivariate analyses 
of the hazard ratio for death were performed 
using Cox proportional hazards regression. 
Chi square testing and Spearman’s rank 
correlation were used to evaluate the asso-
ciations of BMI1 with CSC markers and radi-
ation sensitivity. Statistical analyses were 
performed using SPSS version 18.0 (SPSS 
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Expression of BMI1 protein
Expression of BMI1 in cervical neoplasia was 
investigated by IHC; the cancer specimens and 
IHC histoscores were analyzed with digital 
image software. The representative IHC expres-
sion of BMI1 is presented in Figure 1. As indi-
cated, BMI1 expression was clearly evident in 
the nucleus.
Of the 375 patient’s specimens, 106 of 150 
cancers (70.6%) showed high expression of 
BMI1, while 167 of 225 CIN (74.2%) showed 
high expression (cut-off value: 7). The associa-
tions of BMI1 expression with the cervical can-
cer patients’ clinicopathologic characteristics 
are summarized in Table 2. As indicated, BMI1 
expression in cervical cancer was significantly 
higher than in normal cervix or CIN lesion (Table 
2). However, there was no association between 
BMI1 expression and cancer stage, tumor dif-
ferentiation, tumor cell type, tumor size, lym-
phovascular space invasion, or LN metastasis 
(Table 2).
Survival outcome of BMI1 expression
Five-year disease-free and overall survivals 
were analyzed by Kaplan-Meier plot as shown 
in Figure 2. In the disease-free survival analysis 
of BMI1, the number of recurrences was 17 of 
106 in high-expression patients, while 15 re- 
currences of 44 low-expression patients were 
shown. High expression of BMI1 showed a bet-
ter disease-free survival rate than that of the 
low-expression group (P=0.017) (Figure 2A). In 
the overall survival analysis for BMI1 expres-
sion, 8 deaths in 106 high expressions oc- 
curred, while 9 deaths were observed in 44 low 
expressions. High expression of BMI1 showed 
a better overall survival rate than that of the 
low expression group, and significantly (P= 
0.035) (Figure 2B).
Multivariate survival analysis
Cox proportional multivariate analysis was per-
formed to investigate the association of BMI1 
with survival outcome (Table 3). The FIGO stage 
Figure 2. Five-year disease-free and overall survivals analyzed by Kaplan-Meier plot.
Table 3. Multivariate survival analysis of disease-free and overall survival of 150 patients with cervi-
cal cancer
Disease-free survival Overall survival
Hazard ratio [95% CI] p value Hazard ratio [95% CI] p value
FIGO stage (≥IIB) 5.86 [2.70-12.70] <0.001 3.01 [1.13-8.01] 0.027
Tumor size (>4 cm) 0.68 [0.34-1.50] 0.346 1.30 [0.28-3.48] 0.601
Tumor differentiation (poor) 0.90 [0.44-1.84] 0.784 1.26 [0.50-3.21] 0.616
BMI1 (high expression) 0.43 [0.21-0.88] 0.021 0.34 [0.13-0.90] 0.030
BMI1 expression in cervical cancer
1854 Int J Clin Exp Pathol 2016;9(2):1849-1857
and BMI1 showed statistical significances in 
disease-fee and overall survival. High expres-
sion of BMI1 presented a 0.43 hazard ratio for 
disease-free survival and a 0.34 hazard ratio 
for overall survival relative to low expression of 
BMI1 with statistical significance (P=0.021 and 
0.03, respectively).
Associations with cancer stem cell markers 
and radiation sensitivity
To determine the association of BMI1 with stem 
cell markers SOX2 and OCT4 in malignant and 
premalignant lesions, a Chi square test was 
used (Table 4). In the CIN lesions, BMI1 pre-
sented significant correlations with SOX2 and 
OCT4 (P=0.031 and 0.006, respectively), whe- 
reas in the cervical cancer cases, there were no 
such associations (Table 3). Of the 47 patients 
who received radiation therapy, those that were 
radiation sensitive numbered 40. Among these 
radiation-sensitive patients, the rate of high 
expression of BMI1 was 70% (28/40), whereas 
among the radiation-resistant patients it was 
28.6% (2/7). The correlation of high BMI1 
expression with radiation sensitivity was most 
significant in cervical cancer (P=0.049).
Additionally, the association between BMI1 his-
toscore and human papillomavirus (HPV) titer 
was investigated, results for which are summa-
rized in Table 5. In invasive cervical cancer, 
BMI1 histoscore presented a significantly nega-
tive correlation with HPV level by Spearman’s 
rank correlation (P=0.045).
Discussion
This study evaluated the prognostic value of 
BMI1 in cervical cancer. BMI1 was highly ex- 
pressed in cervical cancer compared with nor-
mal cervix and CIN lesion. In a Kaplan-Meier 
survival analysis, high expression of BMI1 was 
associated with favorable disease-free survival 
and overall survival; according to a multivariate 
analysis meanwhile, it produced a significantly 
low hazard ratio for death. BMI1 also was close-
ly associated with CSC markers OCT4 and SOX2 
in CIN lesion, whereas there was no such asso-
ciation in cervical cancer. Additionally, BMI1 
expression was observed in radiation-sensitive 
cervical cancer, suggesting that BMI1 presents 
positive prognostic outcomes.
BMI1, regarded as an oncogene, has been sug-
gested to play a role in cancer stem cells. BMI1 
is involved in EMT and induces stem cell prop-
erties by cooperating with Snail or Twist1. Over-
expression of BMI1 inactivates tumor suppres-
sor genes p16 and p19ARF by suppressing the 
INK4a locus, eventually regulating apoptosis 
and senescence [7, 8]. BMI1 expression is ob- 
served in various cancers including lung, co- 
lorectal, breast and oral, and high expression is 
expected to be associated with poor prognosis 
[14, 17-19]. Our present results, contrastingly, 
presented favorable survival outcomes; in fa- 
ct, high expression of BMI1 was observed in 
patients with radio-sensitive cervical cancer. 
Similarly to our findings moreover, associations 
of improved survival with high expression of 
BMI1 have been reported for glioblastoma, 
breast, and colorectal cancers [20-22]. BMI1 
has been posited to have multiple function- 
alities, among which are oncogenic and tum- 
or-suppressive roles [13, 24]. BMI1 has been 
reported to dysregulate tumor suppressor ge- 
nes Rb and p53 by suppressing p16INKa and 
p19ARF through inactivation of INK4a [5, 6]. 
Table 4. Association of BMI1 with CSC markers and radiation resistance in cervical cancer or CIN
BMI1 expression in CIN BMI1 expression in cervical cancer
Low (%) High (%) No p value Low (%) High (%) No p value
SOX2-low expression 13 (44.8%) 16 (55.2%) 29 0.031 9 (26.5%) 25 (73.5%) 34 0.463
SOX2-high expression 29 (24.8%) 88 (75.2%) 117 30 (29.4%) 72 (70.6%) 102
OCT4-low expression 24 (41.4%) 34 (58.6%) 58 0.006 13 (25.0%) 39 (75.0%) 52 0.345
OCT4-high expression 56 (27.7%) 146 (72.3%) 202 25 (27.9%) 59 (72.1%) 84
Radiation sensitive NA 12 (30.0%) 28 (70.0%) 40 0.049
Radiation resistant 5 (71.4%) 2 (28.6%) 7
Table 5. Association between BMI1 and HPV 
titer in cervical cancer
HPV titer
Spearman’s rho BMI1 Histoscore r -0.381
p 0.045
N 28
BMI1 expression in cervical cancer
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Although BMI1 prevents TP53 activation by 
suppressing INK4a/ARF, TP53 activation is not 
selectively expressed by BMI1 over-expression; 
and in any case, other oncogenic activations 
express INK4a/ARF as part of the tumor-sup-
pressive response. Notably, TP53 activation by 
DNA damage occurs via ATM/ATR signaling 
rather than via ARF, which implies that treat-
ment of tumors with BMI1 expression by DNA 
damage might activate the TP53 pathway to 
induce apoptosis [25, 26]. Pietersen et al. 
reported that BMI1 over-expression was asso-
ciated with favorable prognosis in patients 
undergoing chemotherapy or hormone therapy 
for breast cancer [24]. Our result also indicated 
that BMI1 over-expression is associated with 
radio-sensitivity and improved survival. Both 
our data and Pietersen et al’s suggest that 
BMI1 over-expression can result in favorable 
prognosis in cases of DNA-damaged tumor 
after chemotherapy or radiation therapy. Fur- 
thermore, high expression of BMI1 is closely 
correlated with expression of trimethylation of 
lysine 27 on histone H3 (H3K27me3), which 
involves in epigenetic regulator, and that both 
H3K27me3 and PCG proteins including BMI1 
might prevent aberrant expression of oncogene 
[20, 27].
HPV is a well known causative agent of cervical 
cancer, and its infection has been reported to 
be involved in down-regulation of BMI1 [28]. 
HPV16 E6 and E7 oncogenes result in down-
regulation of the PRC1 protein BMI1, but also 
induce over-expression of the PRC2 protein 
EZH2, suggesting progression of HPV 16-asso-
ciated cancers [28]. Furthermore, BMI1 protein 
has been negatively correlated with high-risk 
HPV-positive DNA and mRNA in penile carcino-
ma [29]. In our results, HPV level also present-
ed a significantly inverse correlation with BMI1 
protein expression in cervical cancer. Intere- 
stingly, whereas BMI1 is known to suppress 
p16INK4a expression, a known surrogate ma- 
rker of CIN, HPV infection induces p16INK4a 
expression, which fact supports the mostly 
expressed and known to be a surrogate marker 
of CIN, supporting BMI1 function’s restriction 
by HPV infection in cervical cancer.
Reports of the association of prognosis with 
BMI1 expression in cervical cancer have been 
sparse. In a previous analysis by IHC, high ex- 
pression of BMI1 was correlated with poor over-
all survival, contrary to our present result [30]. 
Although the case of this disparity is not yet 
clear, interpretation of the results of IHC with 
different antibodies and cohort tissue samples 
might produce conflict results. In this study, we 
evaluated BMI1 protein expression by automat-
ed digital image analysis, which offers the 
advantages of objectivity, reproducibility and 
quantitative assessment of IHC stains [31, 32]. 
Although our interpretation method is relatively 
objective, survival outcome as a correlate with 
BMI1 expression remains controversial; further 
investigation of BMI1-related prognosis is re- 
quired.
BMI1 is well known to be required for the self-
renewal of CSCs as a key mediator of SOX2 or 
cooperator with OCT4 [16, 33, 34]. In our study, 
the correlation of BMI1 with stem cell markers 
such as OCT4 and SOX2 was investigated. In 
CIN lesion, BMI1 was significantly correlated 
with OCT4 and SOX2, but in invasive cervical 
cancer, no such association was observed. 
Kang et al. reported BMI1 expression in the 
oral mucosal tissue of precancerous and can-
cerous tissue [12]. Indeed, BMI1 expression 
occurs, through P16INK4a-independent path-
ways, at a very early stage of carcinogenesis. 
For this reason, BMI1 maintains the associa-
tion with CSCs in premalignant lesion but, in 
malignant lesion, might lose the association 
with CSC and its phenotype during tumor pro- 
gression.
Our survival-prognosis results represent a rela-
tively large number of clinical tissue samples; 
however, the number of radiation therapy pa- 
tients was limited. The association between 
BMI1 expression and radiation sensitivity re- 
quires further investigation.
In conclusion, high expression of BMI1 was as- 
sociated with improved disease-free survival 
and overall survival in a multivariate analysis. 
BMI1 was positively correlated with CSC mark-
ers OCT4 and SOX2 in CIN lesion, whereas in 
cervical cancer, no association of this kind was 
observed. Notably, BMI1 expression was obse- 
rved in radiation-sensitive cervical cancer, sug-
gesting its positive prognostic indication.
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